Einstein/Montefiore Department of Medicine

Grand Rounds

Medicine Grand Rounds: Targeting of the Atherogenic Dyslipidemia Complex - The Next Frontier in CVD Prevention beyond LDL Lowering

Einstein/Montefiore Department of Medicine Grand Rounds

Thursday, May 05, 2016

8:00 AM: Forchheimer Medical Science Building 3rd Floor Lecture Hall

Speaker & Info

Gary Lewis, MD, FRCPC
Senior Scientist, Toronto General Research Institute (TGRI)

Repeated at 12:15 pm, Cherkasky Auditorium, Montefiore Medical Center.

enlarge image

Dr. Gary Lewis has made a number of seminal discoveries elucidating the mechanism of blood fat abnormalities in diabetes and prediabetic states. His research has had a major impact on the study of postprandial lipoprotein metabolism, the mechanism of HDL lowering, the mechanism of triglyceride rich lipoprotein overproduction by liver and intestine and the mechanism of free fatty acid impairment of pancreatic insulin secretion, the latter potentially contributing to pancreatic failure and the development of type 2 diabetes. He is internationally recognized as a foremost expert in the field of lipoprotein metabolism in insulin resistance and diabetes.

Dr. Lewis is the recipient of the 2016 Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology Scientific Excellence Award; the 2013 Canadian Society for Clinical Investigation (CSCI) Distinguished Scientist Award and Lecture; a Canada Research Chair in Diabetes; and the Canadian Diabetes Association Young Scientist Award. He has been elected to the American Society for Clinical Investigation and the Canadian Academy for Health Sciences. He has been invited to present his research findings at numerous universities and meetings around the world.

Dr. Lewis completed his medical training in 1982 at the University of Witwatersrand in South Africa, followed by specialty training in internal medicine and then endocrinology at the University of Chicago. He joined the staff of the Toronto General Hospital in 1990, was appointed Head of the Division of Endocrinology at University Health Network and Mount Sinai Hospitals in 2001, Director of the University of Toronto Division of Endocrinology and Metabolism in 2008, and Director of the Banting and Best Diabetes Centre, University of Toronto, in 2011. Dr. Lewis is the principal applicant on a recently awarded $31 million Canadian Network grant in diabetes and its related complications. He is a full professor in the Departments of Medicine and Physiology at the University of Toronto, where he holds the Sun Life Financial Chair in Diabetes and the Drucker Family Chair in Diabetes Research.

Objectives - After attending this activity, participants will be able to:

  1. Understand what is meant by the atherogenic dyslipidemic complex and its relationship to atherosclerotic cardiovascular disease
  2. Understand the underlying genetic and environmental predisposing causes and the pathophysiology of this condition
  3. Understand the body of scientific literature to date of clinical trials that have targeted aspects of the atherogenic dyslipidemia complex and the limitations of those clinical trials
  4. Have an appreciation for promising novel therapies that target aspects of the atherogenic dyslipidemia complex

Accreditation: Albert Einstein College of Medicine designates this educational activity for a maximum of 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity. Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Host: Division of Endocrinology & Diabetes (Department of Medicine)

Click here to log in